BioDelivery Sciences International Aktie - Fundamentalanalyse - Dividendenrendite KGV

BioDelivery Sciences International (ISIN: US09060J1060, WKN: 766464) Kursdatum: 19.06.2018 Kurs: 2,770 USD
Beschreibung Daten
Symbol BDSI
Marktkapitalisierung 156.234.928,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Gesundheitswesen
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet www.bdsi.com
Letztes Bilanz Update 17.03.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 19.06.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-4,81 -4,81 0,01% 5,76 10,08 30,78 2,52 17,60

Firmenbeschreibung

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.bdsi.com